VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis Under Second or Third Line Therapy to Examine Safety, Efficacy, and Immune Biomarkers After Treatment With VXM01
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 04 May 2017
At a glance
- Drugs VXM-01 (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors VAXIMM
- 07 Jun 2017 Biomarkers information updated
- 28 Apr 2017 Planned number of patients changed from 24 to 6.
- 28 Apr 2017 Status changed from recruiting to active, no longer recruiting.